India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The acquisition is based on an enterprise value of Rs. 1,660 crore
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Subscribe To Our Newsletter & Stay Updated
